The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients



Status:Completed
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - Any
Updated:12/9/2017
Start Date:September 2010
End Date:April 2012

Use our guide to learn which trials are right for you!

The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients

The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the
inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active
moderate to severe rheumatoid arthritis.

The primary objective of this study is to evaluate the efficacy of CSP used in combination
with MTX in patients with active moderate to severe RA by evaluating change from baseline in
synovitis and bone edema MRI scores at week 6.

Inclusion Criteria:

- moderate to severe RA (DAS > 4.4)

- at least two swollen and tender joints in one of the hand/ wrist

- patients must have failed at least one non-biologic or biologic DMARDs

- currently receiving MTX therapy

Exclusion Criteria:

- concomitant diseases or pathological conditions that could interfere and impact the
assessment of the study treatment
We found this trial at
2
sites
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Aventura, FL
Click here to add this to my saved trials